Tersus Environmental, LLC
9 News & Press Releases found

Tersus Environmental, LLC news

Officially granted on September 21, 2021, the claims are generally directed towards a method for supplying a mixture comprising ferrous sulfide and zero-valent metal particle reactants into soil pathways to biologically react with dissolved contaminants in groundwater. Further, an organic hydrogen donor is supplied into the soil-pathways to produce anaerobic-conditions to cause indigenous anaerobic bacteria to biodegrade residual concentrations of the contaminants. The claims are also general

Sep. 24, 2021

Tersus Environmental (www.tersusenv.com) announced today that it has achieved a major milestone:10 years of successful business operation. Tersus started in 2011 focusing on the commercialization of Gas Infusion Technology for bioremediation.  Over the course of a decade, Tersus dramatically expanded its operations to become a leading provider of amendments, technologies, and services specific to soil and groundwater remediation.

Tersus star

Jan. 20, 2021

Advancing their strategic vision encompassing in-situ remediation, Tersus Environmental today announced a significant expansion of its global patent portfolio. Tersus has acquired the entire interest in five U.S. Patents. The patents relate to methods for remediating subsurface contaminants through the use of in-situ surfactant and chemical oxidant flushing for complete remediation of contaminants and methods of using same, for which Letters Patent of the United States were issued for U

Oct. 11, 2017

Tersus recieves approval from the Florida Department of Environmental Protection (FDEP), accepting the use of NutriBind™ as an innovative technology in the treatment of contaminated soil and groundwater. While the Florida DEP does not provide brand name endorsements or performance certifications, it does determine product acceptability in the context of environmental regulations, safety and the protection of public health. These approval letters make it easier for Remedia

Apr. 30, 2016

Tersus Environmental announced today that the United States Patent and Trademark Office granted a patent for soil or groundwater remediation using a self-nanoemulsifying oil. The issuance of this patent further validates the innovative nature of Tersus` electron donor technology platform and family of biotechnology-based solutions to manage complex, challenging environmental liabilities.

Officially granted on April 12, 2016, the U.S. patent number for bioremediation

Apr. 30, 2016

Tersus is the worldwide distributor of the leading surfactant technology, TASK™ (Tersus Advanced Surface Kinetics) and related products, including the patented methods for in situ surfactant and chemical oxidation flushing (US Patent Nos. 6913419, 7021863, 7364386, 7,708,496, and 7,677,836). Our anionic surfactant formulations have the unique ability to selectively desorb and liberate sorbed petroleum hydrocarbons from soil and fractured bedrock surfaces allowing for their improved mass

Mar. 4, 2015

When: Thursday, March 20, 2014 
Space is limited. 
Reserve your Webinar seat now at: 
www2.gotomeeting.com/register/712355194

A primary limitation of in-situ remediation processes is the lack of contact between delivered amendments and the contaminants. Many in-situ remediation projects are implemented using slug injections that have

Mar. 12, 2014

Antea®Group, a global engineering and environmental consulting firm, and Tersus Environmental announced today the signing of an Exclusive License Agreement for US Patent No. 7138060.   Under the terms of the agreement, Tersus Environmental will make, market, promote and sell products for sulfate-enhanced bioremediation of contaminated groundwater.   The patent includes a process for using high concentrations of sulfate to stimulate biodegradation of pe

Jun. 26, 2013

SiREM (www.Siremlab.com) and Tersus Environmental (www.tersusenv.com) announced today the signing of a Sales Agency Agreement between the two firms. Under the terms of the agreement, Tersus Environmental will market, promote and sell SiREM’s bioaugmentation cultures – KB-1® and KB-1® Plus – as well as Gene-Trac® molecular testing services and treatability studies.

Si

Feb. 23, 2012